New research

Graybug Vision Announces Presentations on Novel Treatments for Wet AMD and Glaucoma at ARVO 2018 Annual Meeting

Developing Potential Once per Year Treatment for Wet AMD

REDWOOD CITY, Calif.–(BUSINESS WIRE)–Graybug Vision, Inc., a clinical stage pharmaceutical company committed to developing potentially transformative therapies for vision-threatening ocular diseases including wet age-related macular degeneration (wet AMD) and primary open angle glaucoma (POAG), today announced that data from its preclinical research will be highlighted in presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting, taking place from April 29 – May 3 in Honolulu, Hawaii.

“Sunitinib-Loaded Injectable Polymer Depot Formulation for Potential Once per Year Treatment of Neovascular Age-related Macular Degeneration (wet AMD).”

Graybug Vision’s second-generation product, GB-103, is a potential once per year treatment of wet AMD. GB-103 follows Graybug Vision’s lead asset, GB-102, a clinical stage potential twice per year treatment of wet AMD, which is on track to complete enrollment of the first part of a Phase 1/2 study (ADAGIO study) of wet AMD patients in Q2 2018 and to present data at a scientific conference in Q4 2018. Both GB-102 and GB-103 are novel injectable depot formulations intended to gradually release sunitinib, a tyrosine kinase inhibitor that blocks angiogenesis pathways through multiple receptors (e.g., VEGFR receptors). The formulations are being developed to alleviate the treatment burden for wet AMD patients currently receiving intravitreal anti-VEGF agents into the eye every 6 to 8 weeks, on average.
Currently, the most common treatment of glaucoma is the use of eye drops that must be taken every day, and patients frequently forget or have difficulty administering these eye drops, leading to low medical compliance. Graybug Vision’s novel approach for glaucoma leverages its novel prodrug technology to create proprietary compounds combined with its depot delivery technology platform to provide sustained reductions in intraocular pressure for up to 6 months after injection potentially improving compliance and clinical outcomes…….
Read more:
Source: Business wire